FDA grants orphan drug designation for CPI-613 for Burkitt lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rafael Pharmaceuticals Inc. said FDA has granted orphan drug designation to CPI-613, the company’s lead Altered Energy Metabolism Directed drug candidate, for the treatment of Burkitt Lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login